David Escors

Universidad Publica de Navarra — Spain

Medicine · Health Sciences

47h-index7.5kcitations221works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(74), Immunotherapy and Immune Responses(61), CAR-T cell therapy research(46), Immune Cell Function and Interaction(37), Virus-based gene therapy research(35)

Publications221 total

148P High-throughput multiomic profiling of PD-1/LAG-3 signaling uncovers a highly dysfunctional T cell rewiring through MYC inhibition
ESMO Open·2025Open Access
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy
Cancers·2025· 3 citedOpen Access
PD-L1 Domain Organization, Signaling Motifs and Interactors in Cancer Immunotherapy
Preprints.org·2025Open Access
110MO CD8 T cells are responsible for the PD-1, LAG-3 and CBL-B triple blockade therapeutic antitumor effect
ESMO Open·2024Open Access
4P CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Annals of Oncology·2024Open Access
Fractalkine in Health and Disease
International Journal of Molecular Sciences·2024· 13 citedOpen Access
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
EMBO Molecular Medicine·2024· 14 citedOpen Access
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
British Journal of Cancer·2024· 12 citedOpen Access
Assessment of myeloid-derived suppressor cell differentiation ex vivo
Methods in cell biology·2023
Circulating low density neutrophils are associated with resistance to anti‐PD1 immunotherapy in squamous head and neck cancer
Head & Neck·2023· 6 citedOpen Access
15P CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Annals of Oncology·2023Open Access
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy
Nature Metabolism·2023· 44 citedOpen Access
Review of: "Why Backward Time Travel Is Not Possible"
2023Open Access
Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp> / <scp>PD</scp> ‐1 blockade in lung cancer
EMBO Reports·2023· 11 citedOpen Access
COVID-19, ¿una nueva enfermedad inesperada?
Gobierno de Navarra eBooks·2023Open Access
Review of: "Does the Time Dimension has to be Perpendicular to the Space-Dimensions?"
2023Open Access
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
International Journal of Molecular Sciences·2023· 6 citedOpen Access
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
International Journal of Molecular Sciences·2023· 73 citedOpen Access
PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers
2023· 1 citedOpen Access
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Cancers·2023· 81 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Grazyna Kochan(21), Karine Breckpot(15), Hugo Arasanz(14), Ana Bocanegra(11), María Gato(10), Miren Zuazo(10), Luisa Chocarro(8), Luis Enjuanes(7), Thérèse Liechtenstein(7), G. Fernández-Hinojal(6), María Ibáñez-Vea(5), Ruth Vera(5), María Jesús García-Granda(5), Katarzyna Karwacz(5), Frederick Arce(5), Ester Blanco(5), Ruth Vera(5), Mary Collins(5), Alessio Lanna(4), Javier Ortego(4)